NATCOPHARM - Technical Analysis with Chart Patterns & Indicators
← Back to ListKey Parameters
⭐ Technical Rating: 3.2
Show all parameters (20 more)
🧾 Chart Verdict
Short-term entry zones could be established between 815 ₹ - 825 ₹ with a stop-loss order placed just below the 795 ₹ low price level. A successful rebound off this support should trigger an exit around the 860 ₹ – 870 ₹ zone, capitalizing on the potential for upward momentum. Overall, the stock presents a cautious opportunity given the oversold RSI and support levels but requires careful monitoring of the rights issue execution and profit recovery trajectory.
✅ Positive
The price action has established a clear support zone around the 810-820 level, underpinned by consistent volume during this rally. Furthermore, the RSI reading of 31.1 indicates that the stock is currently oversold and could be poised for a rebound.
⚠️ Limitation
[Corrected] Stock P/E (16.3) is actually LOWER than Industry PE (34.8), a discount to industry peers rather than a premium - treat the valuation framing below with that in mind. Despite the recent support level, the significant drop in Qtr Profit Variance (-83.9%) alongside the high Stock P/E (16.3) compared to the industry PE (34.8), suggests potential overvaluation risks should the profit recovery not materialize quickly. The negative MACD signal reinforces this concern regarding sustained momentum.
📉 Company Negative News
Recent news highlights a rights issue of ₹1,300 crore announced by Natco Pharma which, if fully subscribed, would dilute existing shareholders’ holdings and potentially put downward pressure on the stock price. Scanx.trade reports indicate a planned date for the rights issue, providing investors with an advance notice that may already be reflected in the current price action.
📈 Company Positive News
The Q3FY26 results showed revenue of ₹705.4 crore and net profit of ₹151.3 crore, exceeding analyst expectations – signaling operational improvements despite the significant profit drop in the previous quarter. Scanx.trade also highlights an IPO watch for Natco Pharma’s rights issue offering, suggesting strong investor interest within the shares.
🏭 Industry
The pharmaceutical sector is currently experiencing moderate growth driven by increasing healthcare expenditure and generic drug demand. However, competition remains intense and margins are often sensitive to pricing pressures, which is reflected in the industry's relatively high PE ratio compared to Natco Pharma’s current valuation.